A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

NCT07232719 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the medication retatrutide in adults who have obesity or are overweight to see how it affects their body weight over time.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 250 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-11 · est. completion 2027-07

Where 31 sites · United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT07232719 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.

Treatments tested

Retatrutide also known as LY3437943 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Percent Change from Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight
GLP-1 drugs	retatrutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07232719 ↗